New combo aims to extend life in Tough-to-Treat colorectal cancer
NCT ID NCT07286695
First seen Jan 06, 2026 · Last updated May 23, 2026 · Updated 19 times
Summary
This study tests whether a new drug combination (fruquintinib plus trifluridine/tipiracil) works better than a standard combination (bevacizumab plus trifluridine/tipiracil) for people with advanced colorectal cancer that has not responded to prior treatments. About 292 adults aged 18-75 will be randomly assigned to one of the two treatments. The main goal is to see how long the cancer stays under control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, 100000, China
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.